Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Tumor Infiltrating Lymphocytes in Solid Tumors
2024-510779-39-00Phase 2Completed
- Sponsor
- Iovance Biotherapeutics
- Start
- Jun 2024
- Modality
- Cell Therapies
- Countries
- 7
01
Overview
Phase 2, open-label trial of lifileucel in melanoma, head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC) and 1 more (7 cohorts), sponsored by Iovance Biotherapeutics. Primary endpoint: Objective response rate (ORR). Started Jun 2024; status: completed.
02
Drugs
lifileucel
03
Conditions
melanomahead and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-510779-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510779-39-00.